Pioneering Pain Management: High-Frequency Electrical Stimulation Devices

By HEOR Staff Writer

October 27, 2023

The Current Opioid Crisis and the Treatment of Post-Caesarean Pain

Systemic opioids are the medication that is utilised the most frequently, despite the fact that pain management following a caesarean delivery is a complicated issue. Having said that, this method is not without its flaws. The overprescription of opioids is a key cause, and it is estimated that 1.2 million of the caesarean births performed annually in the United States result in the disposal of 12 million unneeded tablets. There is a high likelihood that these unused tablets will be abused, which will contribute to the continuing opioid problem.

 

A Novel Technique for the Management of Pain

A recent study found that devices that use high-frequency electrical stimulation could be an effective solution to the problem. According to the findings of the study, women who had caesarean deliveries followed by transcutaneous treatment using a high-frequency electrical stimulation device required around 47 percent less opioid analgesic medication while they were in the hospital. In addition, these individuals reported levels of discomfort that were comparable to those reported by patients who had used a sham device.

High-frequency electrical stimulation devices

This breakthrough has the potential to constitute a key step towards lowering the use of opioids, avoiding overprescribing, and preventing dependence from developing. Because it is estimated that 36,000 to 72,000 people in the United States develop a dependence on opioids each year after having a caesarean delivery, finding effective measures to reduce opioid use continues to be a public health priority.

Reference url

Recent Posts

Surge in Obesity Intervention Costs in the Netherlands

By HEOR Staff Writer

February 3, 2026

Obesity intervention costs in the Netherlands have skyrocketed, with a Zorginstituut Nederland report detailing a €61.8 million rise from 2021 to 2024 ...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk

By HEOR Staff Writer

February 2, 2026

GLP-1 RA Safety Review Clears Suicidal Risk Concerns In a pivotal GLP-1 RA safety review, the U.S. Food and Drug Administration (FDA) has concluded, following an extensive analysis of clinical and real-world data, that glucagon-l...
Expansion of Generic Medicines Authorization in Portugal
928 New Medicines Authorizations Boost Portugal's Health Access In 2025, Portugal's National Authority for Medicines and Health Products (